中國再保險(01508.HK):非執行董事汪小亞獲委任為董事會戰略與投資委員會委員
格隆匯12月26日丨中國再保險(01508.HK)公佈,公司非執行董事路秀麗不再擔任董事會戰略與投資委員會委員;非執行董事汪小亞獲委任為董事會戰略與投資委員會委員。非執行董事温寧不再擔任董事會風險管理委員會委員;非執行董事劉曉鵬獲委任為董事會風險管理委員會委員。非執行董事路秀麗不再擔任董事會審計委員會委員;非執行董事劉曉鵬獲委任為董事會審計委員會委員。執行董事任小兵不再擔任董事會關聯交易控制委員會主任委員及委員;獨立非執行董事郝演蘇不再擔任董事會關聯交易控制委員會副主任委員,獲委任為該委員會主任委員;非執行董事劉曉鵬獲委任為董事會關聯交易控制委員會委員及副主任委員。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.